Ecor1 Capital, Llc Acquires 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc acquired 6,646 shares of the stock in a transaction dated Thursday, January 2nd. The shares were bought at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares of the company's stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc acquired 65,184 shares of AnaptysBio stock. The shares were purchased at an average cost of $12.92 per share, with a total value of $842,177.28.

AnaptysBio Trading Up 0.9 %

Shares of ANAB stock traded up $0.12 during mid-day trading on Thursday, reaching $13.36. The stock had a trading volume of 465,990 shares, compared to its average volume of 390,740. The company has a market cap of $406.53 million, a P/E ratio of -2.20 and a beta of -0.11. AnaptysBio, Inc. has a 12-month low of $12.51 and a 12-month high of $41.31. The business has a 50-day simple moving average of $20.10 and a 200 day simple moving average of $28.50.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. Research analysts anticipate that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ANAB. Bank of New York Mellon Corp raised its position in shares of AnaptysBio by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 74,510 shares of the biotechnology company's stock worth $1,867,000 after buying an additional 10,423 shares during the period. Rhumbline Advisers grew its holdings in shares of AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company's stock worth $745,000 after purchasing an additional 525 shares during the period. TD Asset Management Inc increased its position in AnaptysBio by 67.3% during the 2nd quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company's stock worth $947,000 after purchasing an additional 15,200 shares in the last quarter. Headlands Technologies LLC raised its holdings in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock valued at $89,000 after buying an additional 2,900 shares during the period. Finally, Renaissance Technologies LLC lifted its position in AnaptysBio by 52.4% during the second quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company's stock valued at $3,827,000 after buying an additional 52,502 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on ANAB. Guggenheim dropped their price target on shares of AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, December 12th. HC Wainwright downgraded shares of AnaptysBio from a "buy" rating to a "neutral" rating and dropped their target price for the company from $52.00 to $19.00 in a research report on Wednesday, December 11th. Wedbush reissued an "outperform" rating and issued a $40.00 price target (down from $42.00) on shares of AnaptysBio in a research report on Wednesday, December 11th. BTIG Research lowered AnaptysBio from a "buy" rating to a "neutral" rating in a report on Monday, December 2nd. Finally, UBS Group upped their target price on AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, AnaptysBio has an average rating of "Moderate Buy" and a consensus target price of $41.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.